Investigational Drug Information for Omecamtiv Mecarbil
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Omecamtiv Mecarbil?
Omecamtiv Mecarbil is an investigational drug.
There have been 12 clinical trials for Omecamtiv Mecarbil.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 6th 2017.
The most common disease conditions in clinical trials are Heart Failure, Ventricular Dysfunction, Left, and Systolic Murmurs. The leading clinical trial sponsors are Cytokinetics, Amgen, and Servier.
There are forty-five US patents protecting this investigational drug and four hundred and seventy international patents.
Summary for Omecamtiv Mecarbil
| US Patents | 45 |
| International Patents | 470 |
| US Patent Applications | 176 |
| WIPO Patent Applications | 139 |
| Japanese Patent Applications | 24 |
| Clinical Trial Progress | Phase 3 (2017-01-06) |
| Vendors | 65 |
Recent Clinical Trials for Omecamtiv Mecarbil
| Title | Sponsor | Phase |
|---|---|---|
| Omecamtiv Mecarbil Post-trial Access Study | Amgen | Phase 3 |
| Omecamtiv Mecarbil Post-trial Access Study | Cytokinetics | Phase 3 |
| Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults | Amgen | Phase 1 |
Clinical Trial Summary for Omecamtiv Mecarbil
Top disease conditions for Omecamtiv Mecarbil
Top clinical trial sponsors for Omecamtiv Mecarbil
US Patents for Omecamtiv Mecarbil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Omecamtiv Mecarbil | See Plans and Pricing | Compounds, compositions and methods | Cytokinetics, Incorporated (South San Francisco, CA) | See Plans and Pricing |
| Omecamtiv Mecarbil | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Omecamtiv Mecarbil | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Omecamtiv Mecarbil | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Omecamtiv Mecarbil | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Omecamtiv Mecarbil | See Plans and Pricing | Fused imidazole derivatives as IDO/TDO inhibitors | SciFluor Life Sciences, Inc. (Cambridge, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Omecamtiv Mecarbil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Omecamtiv Mecarbil | Argentina | AR053405 | 2024-06-17 | See Plans and Pricing |
| Omecamtiv Mecarbil | Australia | AU2005264988 | 2024-06-17 | See Plans and Pricing |
| Omecamtiv Mecarbil | Brazil | BRPI0512193 | 2024-06-17 | See Plans and Pricing |
| Omecamtiv Mecarbil | Canada | CA2570999 | 2024-06-17 | See Plans and Pricing |
| Omecamtiv Mecarbil | China | CN101035525 | 2024-06-17 | See Plans and Pricing |
| Omecamtiv Mecarbil | Cyprus | CY1115716 | 2024-06-17 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
